Drug related morbidity and mortality updating the cost of illness
Prevalence of HCV infection in other WHO regions varies from 0.5% to 1.0%.Depending on the country, hepatitis C virus infection can be concentrated in certain populations (for example, among people who inject drugs) and/or in general populations.
Prices have dropped dramatically in some countries (primarily low-income) due to the introduction of generic versions of these medicines.
Due to the fact that acute HCV infection is usually asymptomatic, few people are diagnosed during the acute phase.
In those people who go on to develop chronic HCV infection, the infection is also often undiagnosed because the infection remains asymptomatic until decades after infection when symptoms develop secondary to serious liver damage.
Liver diseases represent a major cause of morbidity and mortality among persons living with HIV.
Hepatitis C does not always require treatment as the immune response in some people will clear the infection, and some people with chronic infection do not develop liver damage.